Seth Klarman Gains Stake In Akebia Therapeutics


Klarman's Baupost portfolio contained 25,791,678 shares of Keryx at third-quarter end, equating to a 21.4% stake in the company. The value investor bought the position over 2014 and the first half of 2015 at lofty prices averaging around $10 to the mid-teens.



from Biotech News